Comparative tolerability of the HMG-CoA reductase inhibitors

Drug Safety

Volumn 23, Issue 3, 2000, Pages 197-213

  Farmer, J A ^a   Torre Amione, G ^a  

^a BEN TAUB GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 3A4; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CENTRAL NERVOUS SYSTEM DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; LIVER DYSFUNCTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS;

EID: 0033821827     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023030-00003     Document Type: Review

References (56)

1. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
2. The Lipid Research Clinics Program Trial results I. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
3. Randomized trial of cholesterol lowering in 444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease in a broad range of initial cholesterol levels
5. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG CoA reductase inhibitors
6. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin therapy
7. Lens changes in matched normals and hyperlipidemic patients treated with simvastatin for two years
8. No lens changes caused by simvastatin results from a prospective drug safety study
9. Absence of effect of simvastatin on the progression of lens opacities in a randomized, placebo-controlled study
10. HMG CoA reductase inhibitors for hypercholesterolemia
11. Comparison of fluvastatin and lovastatin blood-brain barrier transfer utilizing in vitro and in vivo methods
12. Do cholesterol lowering agents affect brain activity? A comparison of simvastatin, pravastatin and placebo in healthy volunteers
13. Comparison of effects on sleep of lovastatin, pravastatin and placebo in patients with hypercholesterolemia
14. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: A comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolemia
15. Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
16. Central nervous system effects of HMG CoA reductase inhibitors: Lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia
17. Effects of treatment of lovastatin and pravastatin on daytime cognitive performance
18. Lovastatin 5-year safety and efficacy study
19. Efficacy and long term adverse effect pattern of lovastatin
20. Longterm safety and efficacy profile of simvastatin
21. Longterm efficacy and safety of simvastatin alone and in combination therapy and treatment of hypercholesterolemia
22. An overview of the clinical safety profile of atorvastatin, a new HMG CoA reductase inhibitor
23. A multi-center, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in hypercholesterolemia
24. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hyper-cholesterolemia
25. Cerivastatin in primary hyperlipidemia: A multicenter analysis of efficacy and safety
26. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIB/III studies
27. Updated clinical safety experience with fluvastatin
28. Fluvastatin and primary hypercholesterolemia: Efficacy and safety in patients at high risk. An analysis of a clinical trial database
29. Longterm treatment of hypercholesterolemia with fluvastatin: A 52-week multicenter safety and efficacy study
30. Short-term efficacy and safety of pravastatin in 72 children with familial hyper-cholesterolemia
31. Treatment of primary hypercholesterolemia with pravastatin: Efficacy and safety over three years
32. Efficacy and safety of pravastatin in the longterm treatment of elderly patients with hyper-cholesterolemia
33. A multinational study of the effects of low dose pravastatin in patients with noninsulin dependent diabetes mellitus and hypercholesterolemia
34. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia
35. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia
36. Treatment of primary hypercholesterolemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: A double-blind comparative study
37. Efficacy and safety of pravastatin in African-Americans with primary hypercholesterolemia
38. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
39. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
40. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
41. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
42. Acute hepatic failure associated with the use of low dose sustained release niacin
43. Rhabdomyolysis and drug related myopathies
44. Metabolic causes of recurrent rhabdomyolysis
45. HMG CoA reductase inhibitor induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low molecular weight proteins in neonatal rat muscle cell culture
46. Differential sensitivity of C3-C12 striated muscle to lovastatin and pravastatin
47. HMG CoA reductase inhibitor induced L6 myoblast cell death: Involvement of the phosphatidylinositol 3-kinase pathway
48. Plasma coenzyme Q concentrations in patients treated with simvastatin
49. Lipid lowering drugs and mitochondrial function: Effects of HMG CoA reductase inhibitors and serum ubiquinone and blood lactate/pyruvate ratio
50. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans
51. Serum cholesterol and mortality among Japanese American men in the Honolulu Heart Program
52. Low serum cholesterol and mortality: Which is the cause and which is the effect?
53. Range of serum cholesterol values in the population developing coronary artery disease
54. The effect of aggressive lowering of low density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts
55. Rationale, design and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus revascularization treatments (AVERT)
56. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin